A Phase 2 interventional study of elamipretide in Primary Mitochondrial Disease, sponsored by Stealth BioTherapeutics Inc.. Terminated at 4 sites in United States. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2021-12-17.
Sponsored by Stealth BioTherapeutics Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 83 studies in Mitochondrial Diseases with a site in United States — 20 open to participants now, 22 under way, 3 of them phase 3. Mitochondrial Diseases · United States.
Among the 83 studies in Mitochondrial Diseases with a site in United States, this one is the 30th largest by enrollment of the 50 interventional ones that give a count, is one of 5 that started in 2016, is one of 16 in phase 2, and was the 47th registered.
189 studies on the registry are indexed under Mitochondrial Diseases; 60 are open to participants now.
Browse Mitochondrial Diseases studies →20 of the 83 studies in Mitochondrial Diseases with a site in United States are open now. Recruiting first, the newest first:
Pharming Technologies B.V. · Sites in United States, Belgium, Czechia and 6 more countries
Ages 18+
Khondrion BV · Sites in United States, Denmark, France and 4 more countries
Ages 18+
Children's Hospital of Philadelphia · Sites in United States
Ages 8–75 · Healthy volunteers
Children's Hospital of Philadelphia · Sites in United States
Ages 18–65 · Healthy volunteers
University of California, San Diego · Sites in United States
Ages 50+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 41 Mitochondrial Diseases studies recruiting now, 20 (49%) set no upper age limit and 14 (34%) stop at 75 or younger; 19 take children under 18; 17 take healthy volunteers.
This study: 16 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
83 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 21 · Phase 3 11 · Phase 4 3
First in 2000; this study’s year is marked. 5 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 28 is below the median of 35 across 114 interventional studies indexed under Mitochondrial Diseases.
Median enrollment 38 across the 50 interventional studies, 61 across the 31 observational. Of the 54 that completed or were terminated, 23 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
24 of 83 have an industry lead sponsor. The 10 most frequent:
This study is registered under Stealth BioTherapeutics Inc., one of the names counted as Mighty Therapeutics. Under that name alone:
Stealth BioTherapeutics Inc. is the lead sponsor of 30 studies on the registry; 3 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 5 (83%) have results posted.
Mighty Therapeutics has 4 studies filed under Mitochondrial Diseases — fewer than ten, so there is no comparison to draw.
9 of the studies in Mitochondrial Diseases with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05422534Phase 3Vanderbilt University Medical CenterCoQ10 and Exercise for Mitochondrial Dysfunction in Advance Kidney Disease | 2027-06-20 |
| NCT01803906Columbia UniversityTissue Sample Study for Mitochondrial Disorders | 2026-12 |
| NCT02000284University of ArkansasMitochondrial Dysfunction in Autism Spectrum Disorder | 2026-12-31 |
| NCT01694940Columbia UniversityNorth American Mitochondrial Disease Consortium Patient Registry and Biorepository (NAMDC) | 2026-12-31 |
| NCT03639701Columbia UniversityTreatment of TK2 Deficiency With Thymidine and Deoxycytidine | 2026-12-31 |
Add all 9 to your calendar (.ics) → With an account.
Among the 83 studies in Mitochondrial Diseases with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a Phase 2 Open-Label extension study to evaluate the long term safety and tolerability of daily elamipretide injections in patients with genetically confirmed Primary Mitochondrial Disease who previously participated in the SPIMM-202 Clinical Trial
This open-label, non-comparative, extension trial will enroll subjects with genetically confirmed PMD who have completed the End-of-Study Visit in the SPIMM-202 trial. Subjects who do not discontinue or withdraw from the trial will receive treatment with 40 mg SC elamipretide for the shortest of the following: 260 weeks; regulatory approval and commercial availability of elamipretide in the subject's respective country; or termination of the clinical development for elamipretide in subjects with PMD.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Open-label once daily subcutaneous injection of 40mg elamipretide
Drug: elamipretide
40 mg, subcutaneous injections (in the abdomen) daily for the shortest of the following: 260 weeks; regulatory approval and commercial availability of elamipretide in the subject's respective country; or termination of the clinical development for elamipretide in subjects with PMD.
Distance Walked on Six Minute Walk Test
Change From Baseline in Distance Walked (meters) on the Six-Minute Walk Test by Visit
Time frame: Baseline, Month 3, Month 6 and Every 26 weeks for up to 160 weeks
EuroQol 5 Dimensions 5 Levels (EQ-5D-5L)
EuroQol 5 dimensions 5 levels (EQ-5D-5L) by visit. Count of participants per arm, or severity level of dimension. Measures 5 dimensions: mobility, self-care, usual activities, pain/discomfort, anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. Score ranges from 5-25 with lower score=better outcome, and higher score means a worse outcome.
Time frame: Baseline, Month 3, Month 6 and Every 26 weeks for up to 160 weeks
Euroquol Visual Analog Scale
Euroquol Visual Analog Scale (EQ VAS): A patient-reported measure. The visual scale is numbered from 0 to 100, participants are directed as follows: "100 means the best health you can imagine, 0 means the worst health you can imagine. Mark an X on the scale to indicate how your health is TODAY." Higher scores mean better outcome, lower scores mean worse outcome.
Time frame: Baseline, Month 3, Month 6 and Every 26 weeks for up to 160 weeks
NeuroQOL Fatigue Questionnaire
Change from baseline in NeuroQOL Fatigue Questionnaire by visit. Questionnaire is comprised of 8 questions measuring participants incidence of fatigue affecting activities of daily living. Participants respond by choosing one of the following: 1=never, 2=rarely, 3=sometimes, 4=often, 5=always, with a lower score meaning a better outcome with fatigue affecting participant less, and high score meaning a worse outcome, with fatigue affecting the participant more. Total raw scores range from 8-40. Scores were converted to percentages: range0-100%. Change from baseline score: negative number means improved from baseline, positive number means worsened compared to baseline.
Time frame: Baseline, Month 3, Month 6 and Every 26 weeks for up to 160 weeks
Patient Global Assessment : Categorical
Patient Global Assessment \[PGA\] Score by Visit, count of participants. Patient-reported current health status by visit. PGA Scale is as follows: 1=Excellent, 2=Very good, 3=Good, 4=Fair, and 5=Poor. Total score ranges from 1-5. Higher score means worse health status, means worse outcome.
Time frame: Baseline, Month 3, Month 6 and Every 26 weeks for up to 160 weeks
Patient Global Assessment: Continuous Variable
Patient Global Assessment \[PGA\] Score by Visit, Patient-reported current health status by visit. PGA Scale is as follows: 1=Excellent, 2=Very good, 3=Good, 4=Fair, and 5=Poor. Total score ranges from 1-5. Higher score means worse health status, lower score means worse outcome.
Time frame: Baseline, Month 3, Month 6 and Every 26 weeks for up to 160 weeks
Work Limitations Questionnaire
Work Limitations Questionnaire by visit. Comprised of 25 items, in 4 categories, or demands: Mental/Interpersonal, Output Tasks, Physical Tasks, and Time Management, measuring the degree to which employed individuals are experiencing limitations on-the-job due to their health problems, and health-related productivity loss. 1= All of the time (100%), 2= most of the time, 3=some of the time (about 50%), 4=slight bit of time, 5=none of the time (0%), 6=does not apply to my job. (Presenteeism). The WLQ items ask respondents to rate their level of difficulty or ability to perform specific job demands. Scale score range from 0 (limited none of the time=better outcome) to 100 (limited all of the time= worse outcome) and represent the reported amount of time in the prior two weeks respondents were limited on-the-job.
Time frame: Baseline, Month 3, Month 6 and Every 26 weeks for up to 160 weeks
Physician Global Assessment Score (PhGA) by Visit
Physician Global Assessment- Mean Score by visit. PGA Scale asks physician to rate participant's current health status as follows: 1=Excellent, 2=Very good, 3=Good, 4=Fair, and 5=Poor. Total score ranges from 1-5. Higher score means lower health status, worse outcome; lower score means better health status, better outcome.
Time frame: Baseline, Month 3, Month 6 and Every 26 weeks for up to 160 weeks
Physician Global Assessment (PhGA): Categorical
Physician Global Assessment \[PhGA\] Score by Visit, Physician-reported current health status by visit. PhGA Scale is as follows: 1=Excellent, 2=Very good, 3=Good, 4=Fair, and 5=Poor. Total score ranges from 1-5. Higher score means worse health status, means worse outcome.
Time frame: Baseline, Month 3, Month 6 and Every 26 weeks for up to 160 weeks
PMMSA Individual Items
The PMMSA is a patient-reported outcome measure, assessing a participant's "worst feeling" of 10 symptoms during the last 24 hours: tiredness at rest, tiredness during activities, muscle weakness at rest, muscle weakness during activities, balance, vision, abdominal discomfort, muscle pain, numbness, and headache using a 4-point scale: 1=Not at all, 2=Mild, 3=Moderate, and 4=Severe. Max Score =40= worse outcome, Min score= 10= better outcome on scale. PMMSA Individual Items shows number or participants with mild, moderate, severe or no symptoms at all.
Time frame: Baseline, Week 13, 26, 52, 104, 156, End of Study (Week 160)
Total Fatigue Score_Primary Mitochondrial Myopathy Symptom Assessment (PMMSA)
Change from baseline in the Total Fatigue score Primary Mitochondrial Myopathy Symptom Assessment (PMMSA) where participants report their "worst feeling" of 4 symptoms: Tiredness at rest, Tiredness during activities, Muscle weakness at rest, Muscle weakness during activities, at the end of each treatment period. Total fatigue score is sum of Q1 to Q4 only of PMMSA) and is scored as follows: 1=Not at all, 2=Mild, 3=Moderate, and 4=Severe. Total score range is 4-16; lower score means less fatigue and better outcome, higher score means more fatigue and worse outcome. Raw scores were transformed into percentages: 0-100%. Change from baseline: the lower the score, the better the outcome,=less fatigue; the higher the score, means worse outcome= more fatigue.
Time frame: Baseline, Month 3, Month 6 and Every 26 weeks for up to 160 weeks
Total Fatigue Score During Activities_Primary Mitochondrial Myopathy Symptom Assessment (PMMSA)
Change from baseline in the Total Fatigue during Activities score Primary Mitochondrial Myopathy Symptom Assessment (PMMSA) where participants report their "worst feeling" of 2 symptoms: Tiredness during activities, Muscle weakness during activities, at the end of each treatment period. Total fatigue score is sum of Q2 and Q4 only of PMMSA) and is scored as follows: 1=Not at all, 2=Mild, 3=Moderate, and 4=Severe. Total score range is 2-8; lower score means less fatigue and better outcome, higher score means more fatigue and worse outcome. Raw scores were transformed into percentages: 0-100%. Change from baseline: the lower the score, the better the outcome,=less fatigue; the higher the score, means worse outcome= more fatigue.
Time frame: Baseline, Month 3, Month 6 and Every 26 weeks for up to 160 weeks
| Milestone | Elamipretide |
|---|---|
| Started | 28 |
| Completed | 0 |
| Not completed | 28 |
| Withdrew: Physician decision | 22 |
| Withdrew: Withdrawal by subject | 3 |
| Withdrew: Lost to follow-up | 2 |
| Withdrew: Adverse event | 1 |
Change From Baseline in Distance Walked (meters) on the Six-Minute Walk Test by Visit
| meters | Elamipretide |
|---|---|
| Week 13 | 3.6 ± 52.68 |
| Week 26 | -8.6 ± 56.33 |
| Week 52 | -17.6 ± 70.60 |
| Week 78 | -26.2 ± 73.17 |
| Week 104 | -20.9 ± 77.78 |
| Week 130 | -18.9 ± 76.94 |
| Week 156 | -35.0 ± NA |
| End of Trial (Week 160) | -54.0 ± 70.30 |
EuroQol 5 dimensions 5 levels (EQ-5D-5L) by visit. Count of participants per arm, or severity level of dimension. Measures 5 dimensions: mobility, self-care, usual activities, pain/discomfort, anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. Score ranges from 5-25 with lower score=better outcome, and higher score means a worse outcome.
| Participants | No Problem | Slight Problem | Moderate Problem | Severe Problem | Extreme Problem |
|---|---|---|---|---|---|
| Baseline: Anxiety/Depression | 12 | 8 | 4 | 3 | 1 |
| Baseline: : Mobility | 2 | 10 | 11 | 5 | 0 |
| Baseline: : Pain/Discomfort | 4 | 5 | 15 | 4 | 0 |
| Baseline: : Self-Care | 12 | 10 | 5 | 0 | 1 |
| Baseline: : Usual Activities | 5 | 7 | 12 | 4 | 0 |
| Week 13 Anxiety/Depression | 16 | 6 | 5 | 1 | 0 |
| Week 13 : Mobility | 7 | 7 | 12 | 1 | 1 |
| Week 13 : Pain/Discomfort | 4 | 12 | 8 | 3 | 1 |
| Week 13 : Self-Care | 18 | 7 | 2 | 0 | 1 |
| Week 13 : Usual Activities | 6 | 15 | 5 | 0 | 2 |
| Week 26 Anxiety/Depression | 16 | 6 | 5 | 0 | 0 |
| Week 26 : Mobility | 5 | 6 | 12 | 4 | 0 |
| Week 26 : Pain/Discomfort | 8 | 11 | 5 | 2 | 1 |
| Week 26 : Self-Care | 17 | 7 | 3 | 0 | 0 |
| Week 26 : Usual Activities | 6 | 13 | 7 | 1 | 0 |
| Week 56 Anxiety/Depression | 14 | 5 | 4 | 1 | 1 |
| Week 56 : Mobility | 6 | 6 | 4 | 9 | 0 |
| Week 56 : Pain/Discomfort | 6 | 8 | 9 | 2 | 0 |
| Week 56 : Self-Care | 16 | 6 | 2 | 1 | 0 |
| Week 56: Usual Activities | 8 | 9 | 5 | 3 | 0 |
| Week 78 Anxiety/Depression | 12 | 6 | 3 | 2 | 1 |
| Week 78 : Mobility | 5 | 8 | 8 | 2 | 1 |
| Week 78 : Pain/Discomfort | 4 | 14 | 5 | 1 | 0 |
| Week 78 : Self-Care | 15 | 6 | 2 | 1 | 0 |
| Week 78 : Usual Activities | 5 | 12 | 6 | 1 | 0 |
| Week 104 Anxiety/Depression | 10 | 7 | 4 | 0 | 1 |
| Week 104 : Mobility | 4 | 5 | 10 | 2 | 1 |
| Week 104 : Pain/Discomfort | 5 | 8 | 9 | 0 | 0 |
| Week 104 : Self-Care | 15 | 4 | 1 | 2 | 0 |
| Week 104 : Usual Activities | 3 | 13 | 4 | 2 | 0 |
| Week 130 Anxiety/Depression | 7 | 8 | 3 | 4 | 0 |
| Week 130 : Mobility | 7 | 4 | 8 | 3 | 0 |
| Week 130 : Pain/Discomfort | 7 | 6 | 5 | 4 | 0 |
| Week 130 : Self-Care | 14 | 5 | 1 | 2 | 0 |
| Week 130 : Usual Activities | 6 | 8 | 6 | 1 | 1 |
| Week 156 Anxiety/Depression | 0 | 0 | 1 | 0 | 0 |
| Week 156 : Mobility | 1 | 0 | 0 | 0 | 0 |
| Week 156 : Pain/Discomfort | 0 | 0 | 1 | 0 | 0 |
| Week 156 : Self-Care | 1 | 0 | 0 | 0 | 0 |
| Week 156 : Usual Activities | 0 | 1 | 0 | 0 | 0 |
| End of Study (Week 160) Anxiety/Depression | 9 | 6 | 4 | 1 | 1 |
| End of Study (Week 160) : Mobility | 3 | 5 | 9 | 4 | 0 |
| 21End of Study (Week 160) : Pain/Discomfort | 4 | 7 | 8 | 2 | 0 |
| End of Study (Week 160) : Self-Care | 9 | 8 | 3 | 1 | 0 |
| End of Study (Week 160) : Usual Activities | 5 | 7 | 6 | 2 | 1 |
Euroquol Visual Analog Scale (EQ VAS): A patient-reported measure. The visual scale is numbered from 0 to 100, participants are directed as follows: "100 means the best health you can imagine, 0 means the worst health you can imagine. Mark an X on the scale to indicate how your health is TODAY." Higher scores mean better outcome, lower scores mean worse outcome.
| score on a scale | Elamipretide |
|---|---|
| Baseline | 65.29 ± 17.83 |
| Week 13 | 65.44 ± 22.68 |
| Week 26 | 62.70 ± 21.23 |
| Week 52 | 70.52 ± 21.27 |
| Week 78 | 64.88 ± 22.18 |
| Week 104 | 67.23 ± 21.75 |
| Week 130 | 72.18 ± 21.38 |
| Week 156 | 60.00 ± NA |
| End of Trial (Week 160) | 60.48 ± 23.28 |
Change from baseline in NeuroQOL Fatigue Questionnaire by visit. Questionnaire is comprised of 8 questions measuring participants incidence of fatigue affecting activities of daily living. Participants respond by choosing one of the following: 1=never, 2=rarely, 3=sometimes, 4=often, 5=always, with a lower score meaning a better outcome with fatigue affecting participant less, and high score meaning a worse outcome, with fatigue affecting the participant more. Total raw scores range from 8-40. Scores were converted to percentages: range0-100%. Change from baseline score: negative number means improved from baseline, positive number means worsened compared to baseline.
| score on a scale | Elamipretide |
|---|---|
| Week 13 | -8.39 ± 16.43 |
| Week 26 | -9.33 ± 16.40 |
| Week 52 | -10.88 ± 17.48 |
| Week 78 | -6.79 ± 17.07 |
| Week 104 | -8.27 ± 18.61 |
| Week 130 | -6.77 ± 15.69 |
| Week 156 | 13.00 ± NA |
| End of Study (Week 21 up to Week 160) | -2.67 ± 17.38 |
Patient Global Assessment \[PGA\] Score by Visit, count of participants. Patient-reported current health status by visit. PGA Scale is as follows: 1=Excellent, 2=Very good, 3=Good, 4=Fair, and 5=Poor. Total score ranges from 1-5. Higher score means worse health status, means worse outcome.
| Participants | Elamipretide |
|---|---|
| Baseline — Excellent | 1 |
| Baseline — Fair | 11 |
| Baseline — Good | 9 |
| Baseline — Poor | 5 |
| Baseline — Very Good | 2 |
| Week 13 — Excellent | 0 |
| Week 13 — Fair | 6 |
| Week 13 — Good | 12 |
| Week 13 — Poor | 2 |
| Week 13 — Very Good | 6 |
| Week 26 — Excellent | 1 |
| Week 26 — Fair | 10 |
| Week 26 — Good | 8 |
| Week 26 — Poor | 3 |
| Week 26 — Very Good | 5 |
| Week 52 — Excellent | 0 |
| Week 52 — Fair | 3 |
| Week 52 — Good | 13 |
| Week 52 — Poor | 4 |
| Week 52 — Very Good | 5 |
| Week 78 — Excellent | 0 |
| Week 78 — Fair | 7 |
| Week 78 — Good | 10 |
| Week 78 — Poor | 4 |
| Week 78 — Very Good | 3 |
| Week 104 — Excellent | 0 |
| Week 104 — Fair | 7 |
| Week 104 — Good | 8 |
| Week 104 — Poor | 2 |
| Week 104 — Very Good | 5 |
| Week 130 — Excellent | 1 |
| Week 130 — Fair | 6 |
| Week 130 — Good | 10 |
| Week 130 — Poor | 4 |
| Week 130 — Very Good | 1 |
| Week 156 — Excellent | 0 |
| Week 156 — Fair | 1 |
| Week 156 — Good | 0 |
| Week 156 — Poor | 0 |
| Week 156 — Very Good | 0 |
| End of Study End of Study (Week 21 up to Week 160) — Excellent | 0 |
| End of Study End of Study (Week 21 up to Week 160) — Fair | 8 |
| End of Study End of Study (Week 21 up to Week 160) — Good | 9 |
| End of Study End of Study (Week 21 up to Week 160) — Poor | 3 |
| End of Study End of Study (Week 21 up to Week 160) — Very Good | 1 |
Patient Global Assessment \[PGA\] Score by Visit, Patient-reported current health status by visit. PGA Scale is as follows: 1=Excellent, 2=Very good, 3=Good, 4=Fair, and 5=Poor. Total score ranges from 1-5. Higher score means worse health status, lower score means worse outcome.
| score on a scale | Elamipretide |
|---|---|
| Baseline | 3.61 ± 0.99 |
| Week 13 | 3.15 ± 0.88 |
| Week 26 | 3.15 ± 0.88 |
| Week 52 | 3.24 ± 0.97 |
| Week 78 | 3.50 ± 0.93 |
| Week 104 | 3.27 ± 0.94 |
| Week 130 | 3.50 ± 1.01 |
| Week 156 | 4.00 ± NA |
| End of Trial (Week 160) | 3.62 ± 0.80 |
Work Limitations Questionnaire by visit. Comprised of 25 items, in 4 categories, or demands: Mental/Interpersonal, Output Tasks, Physical Tasks, and Time Management, measuring the degree to which employed individuals are experiencing limitations on-the-job due to their health problems, and health-related productivity loss. 1= All of the time (100%), 2= most of the time, 3=some of the time (about 50%), 4=slight bit of time, 5=none of the time (0%), 6=does not apply to my job. (Presenteeism). The WLQ items ask respondents to rate their level of difficulty or ability to perform specific job demands. Scale score range from 0 (limited none of the time=better outcome) to 100 (limited all of the time= worse outcome) and represent the reported amount of time in the prior two weeks respondents were limited on-the-job.
| score on a scale | Elamipretide |
|---|---|
| Mental/Interpersonal: Baseline | 67.59 ± 15.58 |
| Mental/Interpersonal: Week 13 | 71.33 ± 20.00 |
| Mental/Interpersonal: Week 26 | 72.00 ± 18.54 |
| Mental/Interpersonal: Week 52 | 75.06 ± 19.37 |
| Mental/Interpersonal: Week 78 | 70.62 ± 20.02 |
| Mental/Interpersonal: Week 104 | 68.57 ± 17.42 |
| Mental/Interpersonal: Week 130 | 66.11 ± 24.77 |
| Mental/Interpersonal: End of Trial (Week 160) | 74.72 ± 19.66 |
| Output Task: Baseline | 69.67 ± 20.99 |
| Output Task: Week 13 | 75.20 ± 21.89 |
| Output Task: Week 26 | 75.20 ± 18.16 |
| Output Task: Week 52 | 71.56 ± 18.05 |
| Output Task: Week 78 | 61.50 ± 20.28 |
| Output Task: Week 104 | 59.33 ± 25.85 |
| Output Task: Week 130 | 73.00 ± 22.50 |
| Output Task: End of Trial (Week 160) | 71.00 ± 19.91 |
| Physical Task: Baseline | 56.39 ± 23.37 |
| Physical Task Week 13 | 58.67 ± 17.37 |
| Physical Task Week 26 | 55.00 ± 11.57 |
| Physical Task Week 52 | 52.59 ± 14.32 |
| Physical Task Week 78 | 57.78 ± 11.55 |
| Physical Task Week 104 | 56.67 ± 25.53 |
| Physical Task Week 130 | 58.33 ± 23.03 |
| Physical Task: End of Trial (Week 160) | 58.75 ± 23.03 |
| Time Management Baseline | 61.60 ± 23.26 |
| Time Management Week 13 | 72.40 ± 21.54 |
| Time Management Week 26 | 68.00 ± 24.25 |
| Time Management Week 52 | 68.89 ± 25.83 |
| Time Management Week 78 | 72.89 ± 21.43 |
| Time Management Week 104 | 56.67 ± 27.76 |
| Time Management Week 130 | 57.71 ± 29.11 |
| Time Management End of Trial (Week 160) | 68.57 ± 24.92 |
Physician Global Assessment- Mean Score by visit. PGA Scale asks physician to rate participant's current health status as follows: 1=Excellent, 2=Very good, 3=Good, 4=Fair, and 5=Poor. Total score ranges from 1-5. Higher score means lower health status, worse outcome; lower score means better health status, better outcome.
| score on a scale | Elamipretide |
|---|---|
| Baseline | 3.32 ± 0.61 |
| Week 13 | 3.11 ± 0.80 |
| Week 26 | 3.00 ± 0.73 |
| Week 52 | 2.72 ± 0.84 |
| Week 78 | 3.25 ± 0.79 |
| Week 104 | 3.18 ± 0.85 |
| Week 130 | 3.18 ± 0.73 |
| Week 156 | 5.00 ± NA |
| End of Study (Week 160) | 3.40 ± 0.60 |
Physician Global Assessment \[PhGA\] Score by Visit, Physician-reported current health status by visit. PhGA Scale is as follows: 1=Excellent, 2=Very good, 3=Good, 4=Fair, and 5=Poor. Total score ranges from 1-5. Higher score means worse health status, means worse outcome.
| Participants | Excellent | Fair | Good | Poor | Very Good |
|---|---|---|---|---|---|
| Baseline | 0 | 8 | 18 | 1 | 1 |
| Week 13 | 0 | 7 | 13 | 1 | 6 |
| Week 26 | 1 | 6 | 16 | 0 | 4 |
| Week 52 | 1 | 2 | 12 | 1 | 9 |
| Week 78 | 0 | 8 | 11 | 1 | 4 |
| Week 104 | 0 | 4 | 12 | 2 | 4 |
| Week 130 | 0 | 5 | 13 | 1 | 3 |
| Week 156 | 0 | 0 | 0 | 1 | 0 |
| End of Study (Week 160) | 0 | 6 | 13 | 1 | 0 |
The PMMSA is a patient-reported outcome measure, assessing a participant's "worst feeling" of 10 symptoms during the last 24 hours: tiredness at rest, tiredness during activities, muscle weakness at rest, muscle weakness during activities, balance, vision, abdominal discomfort, muscle pain, numbness, and headache using a 4-point scale: 1=Not at all, 2=Mild, 3=Moderate, and 4=Severe. Max Score =40= worse outcome, Min score= 10= better outcome on scale. PMMSA Individual Items shows number or participants with mild, moderate, severe or no symptoms at all.
| Participants | Elamipretide |
|---|---|
| Baseline: Abdominal Discomfort — Mild | 11 |
| Baseline: Abdominal Discomfort — Moderate | 5 |
| Baseline: Abdominal Discomfort — Not At All | 8 |
| Baseline: Abdominal Discomfort — Severe | 3 |
| Baseline: Balance Problems — Mild | 5 |
| Baseline: Balance Problems — Moderate | 16 |
| Baseline: Balance Problems — Not At All | 1 |
| Baseline: Balance Problems — Severe | 5 |
| Baseline: Headache — Mild | 4 |
| Baseline: Headache — Moderate | 6 |
| Baseline: Headache — Not At All | 16 |
| Baseline: Headache — Severe | 1 |
| Baseline: Muscle Pain — Mild | 6 |
| Baseline: Muscle Pain — Moderate | 12 |
| Baseline: Muscle Pain — Not At All | 5 |
| Baseline: Muscle Pain — Severe | 4 |
| Baseline: Muscle Weakness at Rest — Mild | 12 |
| Baseline: Muscle Weakness at Rest — Moderate | 10 |
| Baseline: Muscle Weakness at Rest — Not At All | 1 |
| Baseline: Muscle Weakness at Rest — Severe | 3 |
| Baseline:Muscle Weakness during Activities — Mild | 2 |
| Baseline:Muscle Weakness during Activities — Moderate | 18 |
| Baseline:Muscle Weakness during Activities — Not At All | 0 |
| Baseline:Muscle Weakness during Activities — Severe | 7 |
| Baseline: Numbness — Mild | 11 |
| Baseline: Numbness — Moderate | 2 |
| Baseline: Numbness — Not At All | 11 |
| Baseline: Numbness — Severe | 3 |
| Baseline: Tiredness at Rest — Mild | 6 |
| Baseline: Tiredness at Rest — Moderate | 13 |
| Baseline: Tiredness at Rest — Not At All | 0 |
| Baseline: Tiredness at Rest — Severe | 8 |
| Baseline: Tiredness during Activities — Mild | 5 |
| Baseline: Tiredness during Activities — Moderate | 13 |
| Baseline: Tiredness during Activities — Not At All | 0 |
| Baseline: Tiredness during Activities — Severe | 9 |
| Baseline: Vision Problems — Mild | 8 |
| Baseline: Vision Problems — Moderate | 9 |
| Baseline: Vision Problems — Not At All | 6 |
| Baseline: Vision Problems — Severe | 4 |
| Week 13:Abdominal Discomfort — Mild | 6 |
| Week 13:Abdominal Discomfort — Moderate | 8 |
| Week 13:Abdominal Discomfort — Not At All | 11 |
| Week 13:Abdominal Discomfort — Severe | 3 |
| Week 13: Balance Problems — Mild | 11 |
| Week 13: Balance Problems — Moderate | 9 |
| Week 13: Balance Problems — Not At All | 1 |
| Week 13: Balance Problems — Severe | 7 |
| Week 13: Headache — Mild | 10 |
| Week 13: Headache — Moderate | 2 |
| Week 13: Headache — Not At All | 14 |
| Week 13: Headache — Severe | 2 |
| Week 13: Muscle Pain — Mild | 11 |
| Week 13: Muscle Pain — Moderate | 7 |
| Week 13: Muscle Pain — Not At All | 7 |
| Week 13: Muscle Pain — Severe | 3 |
| Week 13: Muscle Weakness at Rest — Mild | 13 |
| Week 13: Muscle Weakness at Rest — Moderate | 6 |
| Week 13: Muscle Weakness at Rest — Not At All | 7 |
| Week 13: Muscle Weakness at Rest — Severe | 2 |
| Week 13: Muscle Weakness during Activities — Mild | 10 |
| Week 13: Muscle Weakness during Activities — Moderate | 9 |
| Week 13: Muscle Weakness during Activities — Not At All | 3 |
| Week 13: Muscle Weakness during Activities — Severe | 6 |
| Week 13: Numbness — Mild | 6 |
| Week 13: Numbness — Moderate | 6 |
| Week 13: Numbness — Not At All | 15 |
| Week 13: Numbness — Severe | 1 |
| Week 13: Tiredness at Rest — Mild | 14 |
| Week 13: Tiredness at Rest — Moderate | 10 |
| Week 13: Tiredness at Rest — Not At All | 2 |
| Week 13: Tiredness at Rest — Severe | 2 |
| Week 13: Tiredness during Activities — Mild | 12 |
| Week 13: Tiredness during Activities — Moderate | 11 |
| Week 13: Tiredness during Activities — Not At All | 0 |
| Week 13: Tiredness during Activities — Severe | 5 |
| Week 13: Vision Problems — Mild | 11 |
| Week 13: Vision Problems — Moderate | 7 |
| Week 13: Vision Problems — Not At All | 8 |
| Week 13: Vision Problems — Severe | 2 |
| Week 26:Abdominal Discomfort — Mild | 7 |
| Week 26:Abdominal Discomfort — Moderate | 5 |
| Week 26:Abdominal Discomfort — Not At All | 13 |
| Week 26:Abdominal Discomfort — Severe | 2 |
| Week 26: Balance Problems — Mild | 11 |
| Week 26: Balance Problems — Moderate | 9 |
| Week 26: Balance Problems — Not At All | 1 |
| Week 26: Balance Problems — Severe | 6 |
| Week 26: Headache — Mild | 13 |
| Week 26: Headache — Moderate | 1 |
| Week 26: Headache — Not At All | 12 |
| Week 26: Headache — Severe | 1 |
| Week 26: Muscle Pain — Mild | 11 |
| Week 26: Muscle Pain — Moderate | 7 |
| Week 26: Muscle Pain — Not At All | 7 |
| Week 26: Muscle Pain — Severe | 2 |
| Week 26: Muscle Weakness at Rest — Mild | 13 |
| Week 26: Muscle Weakness at Rest — Moderate | 4 |
| Week 26: Muscle Weakness at Rest — Not At All | 7 |
| Week 26: Muscle Weakness at Rest — Severe | 3 |
| Week 26: Muscle Weakness during Activities — Mild | 10 |
| Week 26: Muscle Weakness during Activities — Moderate | 11 |
| Week 26: Muscle Weakness during Activities — Not At All | 1 |
| Week 26: Muscle Weakness during Activities — Severe | 5 |
| Week 26: Numbness — Mild | 7 |
| Week 26: Numbness — Moderate | 3 |
| Week 26: Numbness — Not At All | 14 |
| Week 26: Numbness — Severe | 3 |
| Week 26: Tiredness at Rest — Mild | 15 |
| Week 26: Tiredness at Rest — Moderate | 8 |
| Week 26: Tiredness at Rest — Not At All | 1 |
| Week 26: Tiredness at Rest — Severe | 3 |
| Week 26: Tiredness during Activities — Mild | 12 |
| Week 26: Tiredness during Activities — Moderate | 10 |
| Week 26: Tiredness during Activities — Not At All | 0 |
| Week 26: Tiredness during Activities — Severe | 5 |
| Week 26: Vision Problems — Mild | 6 |
| Week 26: Vision Problems — Moderate | 9 |
| Week 26: Vision Problems — Not At All | 7 |
| Week 26: Vision Problems — Severe | 5 |
| Week 52: Abdominal Discomfort — Mild | 10 |
| Week 52: Abdominal Discomfort — Moderate | 2 |
| Week 52: Abdominal Discomfort — Not At All | 10 |
| Week 52: Abdominal Discomfort — Severe | 3 |
| Week 52: Balance Problems — Mild | 10 |
| Week 52: Balance Problems — Moderate | 9 |
| Week 52: Balance Problems — Not At All | 1 |
| Week 52: Balance Problems — Severe | 5 |
| Week 52: Headache — Mild | 10 |
| Week 52: Headache — Moderate | 4 |
| Week 52: Headache — Not At All | 10 |
| Week 52: Headache — Severe | 1 |
| Week 52: Muscle Pain — Mild | 8 |
| Week 52: Muscle Pain — Moderate | 6 |
| Week 52: Muscle Pain — Not At All | 9 |
| Week 52: Muscle Pain — Severe | 2 |
| Week 52: Muscle Weakness at Rest — Mild | 8 |
| Week 52: Muscle Weakness at Rest — Moderate | 8 |
| Week 52: Muscle Weakness at Rest — Not At All | 6 |
| Week 52: Muscle Weakness at Rest — Severe | 3 |
| Week 52: Muscle Weakness during Activities — Mild | 12 |
| Week 52: Muscle Weakness during Activities — Moderate | 7 |
| Week 52: Muscle Weakness during Activities — Not At All | 1 |
| Week 52: Muscle Weakness during Activities — Severe | 5 |
| Week 52: Numbness — Mild | 4 |
| Week 52: Numbness — Moderate | 5 |
| Week 52: Numbness — Not At All | 13 |
| Week 52: Numbness — Severe | 3 |
| Week 52:Tiredness at Rest — Mild | 12 |
| Week 52:Tiredness at Rest — Moderate | 8 |
| Week 52:Tiredness at Rest — Not At All | 4 |
| Week 52:Tiredness at Rest — Severe | 1 |
| Week 52:Tiredness during Activities — Mild | 12 |
| Week 52:Tiredness during Activities — Moderate | 10 |
| Week 52:Tiredness during Activities — Not At All | 0 |
| Week 52:Tiredness during Activities — Severe | 3 |
| Week 52:Vision Problems — Mild | 8 |
| Week 52:Vision Problems — Moderate | 9 |
| Week 52:Vision Problems — Not At All | 5 |
| Week 52:Vision Problems — Severe | 3 |
| Week 78: Abdominal Discomfort — Mild | 11 |
| Week 78: Abdominal Discomfort — Moderate | 2 |
| Week 78: Abdominal Discomfort — Not At All | 9 |
| Week 78: Abdominal Discomfort — Severe | 2 |
| Week 78: Balance Problems — Mild | 7 |
| Week 78: Balance Problems — Moderate | 13 |
| Week 78: Balance Problems — Not At All | 1 |
| Week 78: Balance Problems — Severe | 3 |
| Week 78: Headache — Mild | 6 |
| Week 78: Headache — Moderate | 3 |
| Week 78: Headache — Not At All | 14 |
| Week 78: Headache — Severe | 1 |
| Week 78:Muscle Pain — Mild | 10 |
| Week 78:Muscle Pain — Moderate | 5 |
| Week 78:Muscle Pain — Not At All | 7 |
| Week 78:Muscle Pain — Severe | 2 |
| Week 78: Muscle Weakness at Rest — Mild | 10 |
| Week 78: Muscle Weakness at Rest — Moderate | 9 |
| Week 78: Muscle Weakness at Rest — Not At All | 5 |
| Week 78: Muscle Weakness at Rest — Severe | 0 |
| Week 78:Muscle Weakness during Activities — Mild | 8 |
| Week 78:Muscle Weakness during Activities — Moderate | 9 |
| Week 78:Muscle Weakness during Activities — Not At All | 2 |
| Week 78:Muscle Weakness during Activities — Severe | 5 |
| Week 78: Numbness — Mild | 7 |
| Week 78: Numbness — Moderate | 3 |
| Week 78: Numbness — Not At All | 12 |
| Week 78: Numbness — Severe | 2 |
| Week 78:Tiredness at Rest — Mild | 11 |
| Week 78:Tiredness at Rest — Moderate | 8 |
| Week 78:Tiredness at Rest — Not At All | 1 |
| Week 78:Tiredness at Rest — Severe | 4 |
| Week 78:Tiredness during Activities — Mild | 8 |
| Week 78:Tiredness during Activities — Moderate | 10 |
| Week 78:Tiredness during Activities — Not At All | 1 |
| Week 78:Tiredness during Activities — Severe | 5 |
| Week 78: Vision Problems — Mild | 10 |
| Week 78: Vision Problems — Moderate | 5 |
| Week 78: Vision Problems — Not At All | 6 |
| Week 78: Vision Problems — Severe | 3 |
| Week 104: Abdominal Discomfort — Mild | 7 |
| Week 104: Abdominal Discomfort — Moderate | 4 |
| Week 104: Abdominal Discomfort — Not At All | 10 |
| Week 104: Abdominal Discomfort — Severe | 1 |
| Week 104:Balance Problems — Mild | 10 |
| Week 104:Balance Problems — Moderate | 7 |
| Week 104:Balance Problems — Not At All | 1 |
| Week 104:Balance Problems — Severe | 4 |
| Week 104:Headache — Mild | 5 |
| Week 104:Headache — Moderate | 2 |
| Week 104:Headache — Not At All | 14 |
| Week 104:Headache — Severe | 1 |
| Week 104:Muscle Pain — Mild | 10 |
| Week 104:Muscle Pain — Moderate | 7 |
| Week 104:Muscle Pain — Not At All | 5 |
| Week 104:Muscle Pain — Severe | 0 |
| Week 104:Muscle Weakness at Rest — Mild | 10 |
| Week 104:Muscle Weakness at Rest — Moderate | 6 |
| Week 104:Muscle Weakness at Rest — Not At All | 4 |
| Week 104:Muscle Weakness at Rest — Severe | 1 |
| Week 104:Muscle Weakness during Activities — Mild | 8 |
| Week 104:Muscle Weakness during Activities — Moderate | 8 |
| Week 104:Muscle Weakness during Activities — Not At All | 3 |
| Week 104:Muscle Weakness during Activities — Severe | 3 |
| Week 104:Numbness — Mild | 5 |
| Week 104:Numbness — Moderate | 2 |
| Week 104:Numbness — Not At All | 12 |
| Week 104:Numbness — Severe | 3 |
| Week 104: Tiredness at Rest — Mild | 11 |
| Week 104: Tiredness at Rest — Moderate | 6 |
| Week 104: Tiredness at Rest — Not At All | 2 |
| Week 104: Tiredness at Rest — Severe | 3 |
| Week 104:Tiredness during Activities — Mild | 10 |
| Week 104:Tiredness during Activities — Moderate | 9 |
| Week 104:Tiredness during Activities — Not At All | 1 |
| Week 104:Tiredness during Activities — Severe | 2 |
| Week 104: Vision Problems — Mild | 7 |
| Week 104: Vision Problems — Moderate | 5 |
| Week 104: Vision Problems — Not At All | 5 |
| Week 104: Vision Problems — Severe | 5 |
| Week 130: Abdominal Discomfort — Mild | 8 |
| Week 130: Abdominal Discomfort — Moderate | 1 |
| Week 130: Abdominal Discomfort — Not At All | 9 |
| Week 130: Abdominal Discomfort — Severe | 3 |
| Week 130: Balance Problems — Mild | 8 |
| Week 130: Balance Problems — Moderate | 7 |
| Week 130: Balance Problems — Not At All | 1 |
| Week 130: Balance Problems — Severe | 5 |
| Week 130: Headache — Mild | 8 |
| Week 130: Headache — Moderate | 2 |
| Week 130: Headache — Not At All | 11 |
| Week 130: Headache — Severe | 0 |
| Week 130: Muscle Pain — Mild | 7 |
| Week 130: Muscle Pain — Moderate | 4 |
| Week 130: Muscle Pain — Not At All | 7 |
| Week 130: Muscle Pain — Severe | 3 |
| Week 130:Muscle Weakness at Rest — Mild | 9 |
| Week 130:Muscle Weakness at Rest — Moderate | 7 |
| Week 130:Muscle Weakness at Rest — Not At All | 4 |
| Week 130:Muscle Weakness at Rest — Severe | 1 |
| Week 130: Muscle Weakness during Activities — Mild | 8 |
| Week 130: Muscle Weakness during Activities — Moderate | 8 |
| Week 130: Muscle Weakness during Activities — Not At All | 1 |
| Week 130: Muscle Weakness during Activities — Severe | 4 |
| Week 130:Numbness — Mild | 7 |
| Week 130:Numbness — Moderate | 3 |
| Week 130:Numbness — Not At All | 11 |
| Week 130:Numbness — Severe | 0 |
| Week 130:Tiredness at Rest — Mild | 9 |
| Week 130:Tiredness at Rest — Moderate | 9 |
| Week 130:Tiredness at Rest — Not At All | 1 |
| Week 130:Tiredness at Rest — Severe | 2 |
| Week 130: Tiredness during Activities — Mild | 9 |
| Week 130: Tiredness during Activities — Moderate | 10 |
| Week 130: Tiredness during Activities — Not At All | 0 |
| Week 130: Tiredness during Activities — Severe | 2 |
| Week 130:Vision Problems — Mild | 7 |
| Week 130:Vision Problems — Moderate | 7 |
| Week 130:Vision Problems — Not At All | 4 |
| Week 130:Vision Problems — Severe | 3 |
| Week 156: Abdominal Discomfort — Mild | 1 |
| Week 156: Abdominal Discomfort — Moderate | 0 |
| Week 156: Abdominal Discomfort — Not At All | 0 |
| Week 156: Abdominal Discomfort — Severe | 0 |
| Week 156:Balance Problems — Mild | 1 |
| Week 156:Balance Problems — Moderate | 0 |
| Week 156:Balance Problems — Not At All | 0 |
| Week 156:Balance Problems — Severe | 0 |
| Week 156 Headache — Mild | 0 |
| Week 156 Headache — Moderate | 0 |
| Week 156 Headache — Not At All | 1 |
| Week 156 Headache — Severe | 0 |
| Week 156 Muscle Pain — Mild | 0 |
| Week 156 Muscle Pain — Moderate | 0 |
| Week 156 Muscle Pain — Not At All | 0 |
| Week 156 Muscle Pain — Severe | 1 |
| Week 156: Muscle Weakness at Rest — Mild | 0 |
| Week 156: Muscle Weakness at Rest — Moderate | 1 |
| Week 156: Muscle Weakness at Rest — Not At All | 0 |
| Week 156: Muscle Weakness at Rest — Severe | 0 |
| Week 156: Muscle Weakness during Activities — Mild | 0 |
| Week 156: Muscle Weakness during Activities — Moderate | 0 |
| Week 156: Muscle Weakness during Activities — Not At All | 0 |
| Week 156: Muscle Weakness during Activities — Severe | 1 |
| Week 156: Numbness — Mild | 0 |
| Week 156: Numbness — Moderate | 1 |
| Week 156: Numbness — Not At All | 0 |
| Week 156: Numbness — Severe | 0 |
| Week 156:Tiredness at Rest — Mild | 0 |
| Week 156:Tiredness at Rest — Moderate | 0 |
| Week 156:Tiredness at Rest — Not At All | 0 |
| Week 156:Tiredness at Rest — Severe | 1 |
| Week 156:Tiredness during Activities — Mild | 0 |
| Week 156:Tiredness during Activities — Moderate | 0 |
| Week 156:Tiredness during Activities — Not At All | 0 |
| Week 156:Tiredness during Activities — Severe | 1 |
| Week 156:Vision Problems — Mild | 0 |
| Week 156:Vision Problems — Moderate | 0 |
| Week 156:Vision Problems — Not At All | 1 |
| Week 156:Vision Problems — Severe | 0 |
| End of Study: (Week 160) Abdominal Discomfort — Mild | 8 |
| End of Study: (Week 160) Abdominal Discomfort — Moderate | 2 |
| End of Study: (Week 160) Abdominal Discomfort — Not At All | 6 |
| End of Study: (Week 160) Abdominal Discomfort — Severe | 4 |
| End of Study: (Week 160) Balance Problems — Mild | 9 |
| End of Study: (Week 160) Balance Problems — Moderate | 8 |
| End of Study: (Week 160) Balance Problems — Not At All | 0 |
| End of Study: (Week 160) Balance Problems — Severe | 4 |
| End of Study: (Week 160) Headache — Mild | 9 |
| End of Study: (Week 160) Headache — Moderate | 5 |
| End of Study: (Week 160) Headache — Not At All | 7 |
| End of Study: (Week 160) Headache — Severe | 0 |
| End of Study: (Week 160) Muscle Pain — Mild | 5 |
| End of Study: (Week 160) Muscle Pain — Moderate | 9 |
| End of Study: (Week 160) Muscle Pain — Not At All | 4 |
| End of Study: (Week 160) Muscle Pain — Severe | 3 |
| End of Study: (Week 160) Muscle Weakness at Rest — Mild | 8 |
| End of Study: (Week 160) Muscle Weakness at Rest — Moderate | 7 |
| End of Study: (Week 160) Muscle Weakness at Rest — Not At All | 4 |
| End of Study: (Week 160) Muscle Weakness at Rest — Severe | 2 |
| End of Study: (Week 160): Muscle Weakness during Activities — Mild | 3 |
| End of Study: (Week 160): Muscle Weakness during Activities — Moderate | 11 |
| End of Study: (Week 160): Muscle Weakness during Activities — Not At All | 2 |
| End of Study: (Week 160): Muscle Weakness during Activities — Severe | 5 |
| End of Study: (Week 160) Numbness — Mild | 5 |
| End of Study: (Week 160) Numbness — Moderate | 5 |
| End of Study: (Week 160) Numbness — Not At All | 11 |
| End of Study: (Week 160) Numbness — Severe | 0 |
| End of Study: (Week 160) Tiredness at Rest — Mild | 7 |
| End of Study: (Week 160) Tiredness at Rest — Moderate | 9 |
| End of Study: (Week 160) Tiredness at Rest — Not At All | 1 |
| End of Study: (Week 160) Tiredness at Rest — Severe | 4 |
| End of Study: (Week 160) Tiredness during Activities — Mild | 4 |
| End of Study: (Week 160) Tiredness during Activities — Moderate | 10 |
| End of Study: (Week 160) Tiredness during Activities — Not At All | 1 |
| End of Study: (Week 160) Tiredness during Activities — Severe | 6 |
| End of Study: (Week 160): Vision Problems — Mild | 3 |
| End of Study: (Week 160): Vision Problems — Moderate | 9 |
| End of Study: (Week 160): Vision Problems — Not At All | 6 |
| End of Study: (Week 160): Vision Problems — Severe | 3 |
Change from baseline in the Total Fatigue score Primary Mitochondrial Myopathy Symptom Assessment (PMMSA) where participants report their "worst feeling" of 4 symptoms: Tiredness at rest, Tiredness during activities, Muscle weakness at rest, Muscle weakness during activities, at the end of each treatment period. Total fatigue score is sum of Q1 to Q4 only of PMMSA) and is scored as follows: 1=Not at all, 2=Mild, 3=Moderate, and 4=Severe. Total score range is 4-16; lower score means less fatigue and better outcome, higher score means more fatigue and worse outcome. Raw scores were transformed into percentages: 0-100%. Change from baseline: the lower the score, the better the outcome,=less fatigue; the higher the score, means worse outcome= more fatigue.
| score on a scale | Elamipretide |
|---|---|
| Week 13 | -15.12 ± 29.33 |
| Week 26 | -15.06 ± 29.72 |
| Week 52 | -17.01 ± 25.36 |
| Week 78 | -13.41 ± 31.05 |
| Week 104 | -18.65 ± 30.15 |
| Week 130 | -12.92 ± 31.12 |
| Week 156 | 25.00 ± NA |
| End of Trial (Week 160) | -8.33 ± 33.00 |
Change from baseline in the Total Fatigue during Activities score Primary Mitochondrial Myopathy Symptom Assessment (PMMSA) where participants report their "worst feeling" of 2 symptoms: Tiredness during activities, Muscle weakness during activities, at the end of each treatment period. Total fatigue score is sum of Q2 and Q4 only of PMMSA) and is scored as follows: 1=Not at all, 2=Mild, 3=Moderate, and 4=Severe. Total score range is 2-8; lower score means less fatigue and better outcome, higher score means more fatigue and worse outcome. Raw scores were transformed into percentages: 0-100%. Change from baseline: the lower the score, the better the outcome,=less fatigue; the higher the score, means worse outcome= more fatigue.
| score on a scale | Elamipretide |
|---|---|
| Week 13 | -14.20 ± 29.13 |
| Week 26 | -14.10 ± 28.55 |
| Week 52 | -17.36 ± 25.76 |
| Week 78 | -14.49 ± 32.30 |
| Week 104 | -20.63 ± 28.34 |
| Week 130 | -15.00 ± 31.94 |
| Week 156 | 33.33 ± NA |
| End of Trial (Week 160) | -8.33 ± 31.30 |
Collected over Baseline through end of study for up to 260 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Elamipretide | 0/28 (0%) | 8/28 (28.6%) | 28/28 (100%) |
| Event | Elamipretide |
|---|---|
| Pancreatitis acuteGastrointestinal disorders | 1/28 |
| Breast cancer stage INeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/28 |
| HemiparesisNervous system disorders | 1/28 |
| SyncopeNervous system disorders | 1/28 |
| Cerebrovascular accidentVascular disorders | 1/28 |
| Hereditary optic atrophyCongenital, familial and genetic disorders | 1/28 |
| DysphagiaGastrointestinal disorders | 1/28 |
| Ankle fractureInjury, poisoning and procedural complications | 1/28 |
| Troponin increasedInvestigations | 1/28 |
| Renal colicRenal and urinary disorders | 1/28 |
| Event | Elamipretide |
|---|---|
| Injection site pruritusGastrointestinal disorders | 21/28 |
| Injection site pruritusGeneral disorders | 18/28 |
| Injection site massGeneral disorders | 13/28 |
| Injection site urticariaGeneral disorders | 13/28 |
| Injection site painGeneral disorders | 10/28 |
| FallInjury, poisoning and procedural complications | 10/28 |
| NasopharyngitisInfections and infestations | 8/28 |
| Injection site swellingGeneral disorders | 7/28 |
| HeadacheNervous system disorders | 7/28 |
| Chest painGeneral disorders | 6/28 |
All participants for whom Baseline measurements were taken.
| Age, Continuous(years) | Elamipretide |
|---|---|
| Mean | 47.8 ± 11.30 |
| Sex: Female, Male(Participants) | Elamipretide |
|---|---|
| Female | 24 |
| Male | 4 |
| Ethnicity (NIH/OMB)(Participants) | Elamipretide |
|---|---|
| Hispanic or Latino | 1 |
| Not Hispanic or Latino | 27 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Elamipretide |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 27 |
| More than one race | 1 |
| Unknown or Not Reported | 0 |
| Baseline weight(kg) | Elamipretide |
|---|---|
| Mean | 65.93 ± 14.614 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Dec 2016 to primary completion in Mar 2020, 39 months.
Results were first posted in Dec 2021, 1 year 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Elamipretide
Stealth BioTherapeutics Inc. →